Refining the Approach to Patients with Primary Soft Tissue Sarcoma of the Extremities and Trunk Wall: Outcome Improvement Over Time at a Single Institution

2022 ◽  
Author(s):  
Maria Danieli ◽  
Francesco Barretta ◽  
Marco Fiore ◽  
Stefano Radaelli ◽  
Claudia Sangalli ◽  
...  
Keyword(s):  
Soft Tissue ◽  
Soft Tissue Sarcoma ◽  
Single Institution ◽  
Outcome Improvement ◽  
Over Time

scholarly journals Primary extremity soft tissue sarcomas: outcome improvement over time at a single institution

2011 ◽  
Vol 22 (7) ◽  
pp. 1675-1681 ◽  
Author(s):  
A. Gronchi ◽  
R. Miceli ◽  
C. Colombo ◽  
P. Collini ◽  
S. Stacchiotti ◽  
...  
Keyword(s):  
Soft Tissue ◽  
Soft Tissue Sarcomas ◽  
Single Institution ◽  
Outcome Improvement ◽  
Over Time

Prognostic Factors and Oncological Outcomes of 122 Head and Neck Soft Tissue Sarcoma Patients Treated at a Single Institution

2014 ◽  
Vol 22 (1) ◽  
pp. 248-255 ◽  
Author(s):  
Jin Taek Park ◽  
Jong-Lyel Roh ◽  
Seon-Ok Kim ◽  
Kyung-Ja Cho ◽  
Seung-Ho Choi ◽  
...  
Keyword(s):  
Prognostic Factors ◽  
Soft Tissue ◽  
Soft Tissue Sarcoma ◽  
Head And Neck ◽  
Single Institution ◽  
Oncological Outcomes

The management of retroperitoneal soft tissue sarcoma: a single institution experience with a review of the literature

2001 ◽  
Vol 27 (5) ◽  
pp. 491-497 ◽  
Author(s):  
A Pirayesh ◽  
Y Chee ◽  
T.R Helliwell ◽  
M.J Hershman ◽  
S.J Leinster ◽  
...  
Keyword(s):  
Soft Tissue ◽  
Soft Tissue Sarcoma ◽  
Review Of The Literature ◽  
Single Institution ◽  
Retroperitoneal Soft Tissue Sarcoma

Influence of Prereferral Surgery in Soft Tissue Sarcoma: 10 Years’ Experience in a Single Institution

Orthopedics ◽  
2012 ◽  
Vol 35 (8) ◽  
pp. e1214-e1220 ◽  
Author(s):  
Maximilian Zacherl ◽  
Norbert Kastner ◽  
Matthias Glehr ◽  
Susanne Scheipl ◽  
Gerold Schwantzer ◽  
...  
Keyword(s):  
Soft Tissue ◽  
Soft Tissue Sarcoma ◽  
Single Institution

scholarly journals Efficacy of combination-chemotherapy with pirarubicin, ifosfamide, and etoposide for soft tissue sarcoma: a single-institution retrospective analysis

BMC Cancer ◽  
2020 ◽  
Vol 20 (1) ◽  
Author(s):  
Shiro Saito ◽  
Hisaki Aiba ◽  
Satoshi Yamada ◽  
Hideki Okamoto ◽  
Katsuhiro Hayashi ◽  
...  
Keyword(s):  
Soft Tissue ◽  
Soft Tissue Sarcoma ◽  
Adverse Events ◽  
Combination Chemotherapy ◽  
Progressive Disease ◽  
Treatment Phase ◽  
Hematological Toxicity ◽  
Single Institution ◽  
Grade 3

Abstract Background The standard chemotherapy regimens for soft tissue sarcoma are doxorubicin-based. This retrospective study aimed to assess the efficacy and safety of pirarubicin, ifosfamide, and etoposide combination therapy for patients with this disease. Methods Between 2008 and 2017, 25 patients with soft tissue sarcoma were treated with pirarubicin (30 mg/m2, 2 days), ifosfamide (2 g/m2, 5 days), and etoposide (100 mg/m2, 3 days) every 3 weeks. The primary endpoint was overall response, and the secondary endpoint was adverse events of this regimen. Results Responses to this regimen according to RECIST criteria were partial response (n = 9, 36%), stable disease (n = 9, 36%) and progressive disease (n = 7, 28%). During the treatment phase, frequent grade 3 or worse adverse events were hematological toxicities including white blood cell decreases (96%), febrile neutropenia (68%), anemia (68%), and platelet count decreases (48%). No long-term adverse events were reported during the study period. Conclusion This regimen was comparable to previously published doxorubicin-based combination chemotherapy in terms of response rate. Although there were no long-lasting adverse events, based on our results, severe hematological toxicity should be considered.

Interstitial brachytherapy for soft tissue sarcoma: A single institution experience

Brachytherapy ◽  
2007 ◽  
Vol 6 (4) ◽  
pp. 298-303 ◽  
Author(s):  
Michelle L. Mierzwa ◽  
Connie M. McCluskey ◽  
William L. Barrett ◽  
Andrew Lowy ◽  
Jeffrey Sussman ◽  
...  
Keyword(s):  
Soft Tissue ◽  
Soft Tissue Sarcoma ◽  
Interstitial Brachytherapy ◽  
Single Institution

scholarly journals Efficacy of combination-chemotherapy with pirarubicin, ifosfamide, and etoposide for soft tissue sarcoma: A single-institution retrospective analysis

2020 ◽  
Author(s):  
Shiro Saito ◽  
Hisaki Aiba ◽  
Satoshi Yamada ◽  
Hideki Okamoto ◽  
Katsuhiro Hayashi ◽  
...  
Keyword(s):  
Soft Tissue ◽  
Soft Tissue Sarcoma ◽  
Adverse Events ◽  
Combination Chemotherapy ◽  
Progressive Disease ◽  
Treatment Phase ◽  
Hematological Toxicity ◽  
Single Institution ◽  
Grade 3

Abstract Background: The standard chemotherapy regimens for soft tissue sarcoma are doxorubicin-based. This retrospective study aimed to assess the efficacy and safety of pirarubicin, ifosfamide, and etoposide combination therapy for patients with this disease.Methods: Between 2008 and 2017, 25 patients with soft tissue sarcoma were treated with pirarubicin (30 mg/m2, 2 days), ifosfamide (2 g/m2, 5 days), and etoposide (100 mg/m2, 3 days) every 3 weeks. The primary endpoint was overall response, and the secondary endpoint was adverse events of this regimen. Results: Responses to this regimen according to RECIST criteria were partial response (n = 9, 36%), stable disease (n = 9, 36%) and progressive disease (n = 7, 28%). During the treatment phase, frequent grade 3 or worse adverse events were hematological toxicities including white blood cell decreases (96%), febrile neutropenia (68%), anemia (68%), and platelet count decreases (48%). No long-term adverse events were reported during the study period.Conclusion: This regimen was comparable to previously published doxorubicin-based combination chemotherapy in terms of response rate. Although there were no long-lasting adverse events, based on our results, severe hematological toxicity should be considered.

scholarly journals Clinical Application of Hyperthermia to Soft Tissue Sarcoma; Result of Single Institution

2017 ◽  
Vol 33 (4) ◽  
pp. 117-127
Author(s):  
HISAKI AIBA ◽  
SATOSHI YAMADA ◽  
SHINJI MIWA ◽  
TAKANOBU OTSUKA
Keyword(s):  
Soft Tissue ◽  
Soft Tissue Sarcoma ◽  
Clinical Application ◽  
Single Institution
Sign in / Sign up

Export Citation Format

Share Document